Why is nobody tested for insulin resistance until diabetes? Insulin resistance is the upstream condition behind most type 2 diabetes, most fatty liver and a large share of the heart disease in this country and the standard annual physical never measures it. What the physical orders is fasting glucose or its longer-horizon cousin, Hemoglobin A1c (HbA1c). Those are the downstream numbers and they stay normal for years, often a full decade, while insulin climbs to compensate. That decade of silence comes from what gets ordered. The science is not the gap.

Key takeaways
  • Blood sugar stays normal for years while insulin rises to compensate, which is why glucose screens miss insulin resistance.
  • Fasting insulin or HOMA-IR computed from it, catches the upstream state before glucose ever moves.
  • The CDC screening criteria target people whose risk is already advanced, so early cases never meet the threshold.
  • Fasting Insulin and HbA1c are both on the quarterly panel, included in the flat $299 membership four times a year.
  • Insulin resistance is modifiable and the quarterly trend shows whether the intervention is working.

The decade of normal glucose

The pancreas is a compensation machine. As muscle, liver and fat tissue become less responsive to insulin, the pancreas simply makes more of it. Blood sugar holds steady because the extra insulin gets the job done. The report says fasting glucose 92 mg/dL, flagged normal. The flag is honest about glucose and silent about everything else. Fasting insulin in that same person may be two or three times what it should be, doing double duty every hour of every day.

This is the physiological reason the screen misses the condition. You are screening the product, not the factory. The factory, the pancreas, has not failed yet and the product, blood sugar, is still being delivered on time. Hyperinsulinemia is doing the work and nobody is looking at it. By the time glucose moves, the compensation has already begun to fail and the condition is no longer early.

What the screening system does and does not catch

None of this is a conspiracy and it is worth saying so plainly. The CDC's diabetes screening guidance targets adults based on body weight, age and family history and it recommends glucose-based testing. That guidance is a population screening tool and it is reasonable for what it is. What it is not is an early-detection tool for the individual sitting in the exam room with fatigue after meals, central weight that will not move and a family story that worries them.

The consequence shows up in the clinical pattern we see constantly. A patient has a decade of normal fasting glucose reports, a slowly climbing weight, a growing waist, triglycerides drifting upward and HDL drifting down and never once was insulin measured. When it finally is, the number explains the whole story in one line.

Clinical note

Glucose is the downstream number and insulin is the upstream one. The screen orders the downstream number because that is what the guideline names.

What the correct panel measures

The honest workup pairs the upstream and downstream numbers on the same draw. Our quarterly Cardiometabolic Optimization Panel includes Fasting Insulin and Hemoglobin A1c (HbA1c) on every draw, alongside Apolipoprotein B (ApoB), Lipoprotein (A), a Lipid Panel, Standard, Hs-CRP, TSH With Reflex To Free T4 and CBC (Includes Differential And Platelets). From fasting insulin and fasting glucose the HOMA-IR calculation estimates how hard the body is working to hold the line and the trend across quarterly draws is what the clinician treats.

The paired read matters because insulin resistance is not a stand-alone problem. It drives the small, cholesterol-depleted particle pattern that makes LDL-C look clean while ApoB runs high. It suppresses SHBG and complicates hormone optimization in both men and women. It produces the fatty liver that pushes liver enzymes up and the inflammatory state that raises hs-CRP. One draw that reads insulin next to the other systems is what turns those separate flags into one coherent picture.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

What to do with a high fasting insulin

The encouraging part of this condition is that it responds to intervention faster than almost anything else on the panel. Weight loss, muscle gain, dietary composition, sleep and in appropriate cases a branded GLP-1 medication all improve insulin sensitivity measurably within one to two quarters and the quarterly audit shows the movement directly rather than asking you to trust the process.

Where a GLP-1 is part of the plan, it is prescribed as Wegovy, Zepbound, Ozempic or Mounjaro where clinically appropriate and never compounded and it is billed by the pharmacy at its own price with zero markup from us. Our fee is flat, so the titration decision, up or down, carries no profit motive on our side. We make money when you get healthier, not when your dose gets stronger.

Why per-visit billing never catches it

The structural reason is the same one that keeps ApoB and Lp(a) off the standard panel. In the conventional system, each additional test is a line item and each visit that explains it is another receipt, so the comprehensive metabolic panel gets ordered only when symptoms have argued long enough to win the argument. Fasting insulin produces no symptom until the compensation fails, so it loses that argument every time.

The membership model removes the constraint. When the full panel is included in the fee and repeats every 90 days, the rational choice is to order the test that answers the question rather than the test that fits the visit. That is the structural difference between a screening system and an optimization one.

Who this is for and who it is not for

This is for the reader whose glucose has been called normal for years while energy, weight and labs drifted the wrong way, the Concierge Longevity Optimizer who wants the upstream number rather than the downstream one and the high-deductible patient who pays cash for labs anyway and would rather see one defined fee than per-test billing with nobody reading the trend.

It is not for someone who wants a single glucose slip with no clinical relationship attached and labs-only services exist for exactly that purchase. It is not for anyone outside the United States, because our clinicians are licensed in the fifty states. And it is not insurance. The membership pairs with a plan for catastrophic coverage and replaces the primary-care relationship, not the policy.

What the membership costs, stated plainly

The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinical relationship and four quarterly Biomarker Audits a year. It starts with a two month commitment paid as a single $598 hold covering the first two months together, charged only once a clinician accepts you into care. If no clinician can accept you, the hold is released and you are never charged. Once accepted, the first two months are non-refundable. From month three the membership is month to month and you can cancel anytime.

Medication is a separate charge and it never flows through us. Any prescription is written to the pharmacy you choose and billed by that pharmacy at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on that transaction. There is no molecule upcharge and no dose upcharge, ever. One flat fee for the doctor. Zero markup on the medicine. The eligibility check is free and takes a few minutes.

Frequently Asked Questions

Why is nobody tested for insulin resistance until diabetes?

The standard physical orders fasting glucose or HbA1c, which stay normal for years while insulin climbs to compensate. Glucose is the downstream number and insulin is the upstream one. The system screens the downstream number because that is what the screening guidelines name.

Can my glucose be normal while I am insulin resistant?

Yes. That is the typical pattern for a decade. The pancreas compensates by producing more insulin, so blood sugar stays in range while insulin rises, which is exactly what fasting insulin measures and glucose screens miss.

What is HOMA-IR?

A simple calculation from fasting insulin and fasting glucose that estimates how hard your body works to keep blood sugar in range. Higher values indicate greater insulin resistance and the trend across draws matters more than any single value.

What are the early signs of insulin resistance?

Fatigue after meals, central weight gain, rising triglycerides, falling HDL, rising blood pressure, skin tags or darkened skin folds and labs your doctor called normal. Many people have none of these and still carry it, which is why the lab matters more than the symptom list.

Can insulin resistance be reversed?

In many cases it improves substantially with weight loss, muscle gain, diet composition and sleep. GLP-1 therapy can help where appropriate. The quarterly audit tracks whether the intervention is actually working.

Is fasting insulin included in the Biomarker Audit?

Yes. Fasting Insulin is on the quarterly Cardiometabolic Optimization Panel alongside HbA1c, ApoB, Lp(a), hs-CRP, the lipid panel, thyroid and CBC, included in the flat $299 membership four times a year.

How much does the membership cost?

One flat $299 per month covering the doctor and four quarterly lab audits a year, after a two month start paid as one $598 charge covering the first two months together. Medication is billed by your pharmacy separately at pharmacy cost with zero markup.

One last thing

The upstream number that explains a decade of drifting weight and energy is one draw away, it is on our panel every quarter and it is included in the membership rather than billed as a line item. The eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.

Related Guides

References

  1. Centers for Disease Control and Prevention, diabetes risk factors and screening. cdc.gov
  2. Centers for Disease Control and Prevention, diabetes testing. cdc.gov